Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Antibody (T cell) probably leads to lower failure of reversal of acute rejection compared with steroid (stratified by antibody type) (moderate certainty).
1 finding from 1 review
Graft loss censored for death · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) + steroid changes graft loss censored for death compared with steroid alone (very low certainty).
1 finding from 1 review
Death · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in death compared with steroid alone (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Rituximab (B cell) + steroid showed no clear difference in failure of reversal of acute rejection compared with steroid alone (moderate certainty).
1 finding from 1 review
Graft loss or death with a functioning graft · kidney transplant recipients: first rejection episode
Rituximab (B cell) + steroid showed no clear difference in graft loss or death with a functioning graft compared with steroid alone (moderate certainty).
1 finding from 1 review
Death · kidney transplant recipients: first rejection episode
1 finding from 1 review
Treatment adverse events: UTI/pyelonephritis · kidney transplant recipients: first rejection episode
Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).
1 finding from 1 review